ClinicalTrials.gov
public full text
Public Domain
Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer
The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of RC48 plus carboplatin neoadjuvant therapy in HER2 expressed epithelial ovarian cancer patients. The main questions it aims to answer are: * The improvement of complete resection rate and pathological complete rate of this regimen. * The delayed effect of treatment regimens on patient's recurrence.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SGI-110 in Combination With Carboplatin in Ovarian Cancer#839915
- Neoadjuvant Therapy for Ovarian Cancer#898436
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer#1139627
- A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer#881560
- Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer#1044191
Record · ID 889701
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive